866-997-4948(US-Canada Toll Free)

Global Anti-inflammatory Therapeutics Market 2017-2021

Published By :

Technavio

Published Date : Jun 2017

Category :

Metabolic Disorders

No. of Pages : 98 Pages

About Anti-Inflammatory Therapeutics

Inflammation is a part of immune response triggered against harmful stimuli, foreign objects, damaged cells, irritants, and pathogens in the body. The drugs used to treat these symptoms are called anti-inflammatory drugs. It causes the elimination of the initial cause of cell injury, clearance of dead or necrotic cells, and damaged tissue from the site of the inflammatory process and initiates tissue repair.

Technavios analysts forecast the global anti-inflammatory therapeutics market to grow at a CAGR of 6.10% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global anti-inflammatory therapeutics market for 2017-2021. To calculate the market size, the report considers sales of branded, off-label, and generic drugs.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Anti-Inflammatory therapeutics market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
AbbVie
Amgen
Johnson & Johnson
Pfizer

Other prominent vendors
Boehringer Ingelheim
Eli Lilly
Novartis

Market driver
Availability of targeted therapy
For a full, detailed list, view our report

Market challenge
Complex regulatory approval process for biosimilars
For a full, detailed list, view our report

Market trend
Emergence of novel anti-inflammatory drugs
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2021 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.




Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
Market outline
PART 05: Inflammation: An overview
PART 06: Market landscape
Market overview
Five forces analysis
PART 07: Key clinical trial
PART 08: Market segmentation by application
RA
Psoriasis
MS
PART 09: Market segmentation by drug class
Anti-inflammatory biologicals
NSAIDs
Corticosteroids
PART 10: Geographical segmentation
Anti-inflammatory therapeutics market in Americas
Anti-inflammatory therapeutics market in EMEA
Anti-inflammatory therapeutics market in APAC
PART 11: Decision framework
PART 12: Drivers and challenges
Market drivers
Market challenges
PART 13: Market trends
Emergence of novel anti-inflammatory drugs
Increasing strategic alliances by vendors
Advent of biosimilars
PART 14: Vendor landscape
Competitive scenario
PART 15: Key vendor analysis
AbbVie
Amgen
Johnson & Johnson
Pfizer
Other prominent vendors
PART 16: Appendix
List of abbreviations
List of Exhibits
Exhibit 01: Market segmentation of global autoimmune disease market by drug class
Exhibit 02: Snapshot of drivers and challenges present in the market
Exhibit 03: Global anti-inflammatory therapeutics market snapshot
Exhibit 04: Global anti-inflammatory therapeutics market revenue 2016-2021 ($ millions)
Exhibit 05: Opportunity analysis in global anti-inflammatory therapeutics market
Exhibit 06: Five forces analysis
Exhibit 07: Pipeline snapshot
Exhibit 08: Pipeline landscape
Exhibit 09: Purpose of clinical trial
Exhibit 10: Global anti-inflammatory therapeutics market segmentation based on application
Exhibit 11: Global anti-inflammatory therapeutics market based on application 2016 (%)
Exhibit 12: Risk factors responsible for RA
Exhibit 13: National arthritis prevalence rate in the US 2000-2040
Exhibit 14: Drivers and challenges of global anti-inflammatory RA therapeutics market 2016
Exhibit 15: Global anti-inflammatory RA therapeutics market revenue 2016-2021 ($ millions)
Exhibit 16: Drivers and challenges of global anti-inflammatory psoriasis therapeutics market 2016
Exhibit 17: Global anti-inflammatory psoriasis therapeutics market 2016-2021 ($ millions)
Exhibit 18: Drivers and challenges of global anti-inflammatory MS therapeutics market 2016
Exhibit 19: Global anti-inflammatory MS therapeutics market 2016-2021 ($ millions)
Exhibit 20: Global anti-inflammatory therapeutics market segmentation based on drug class
Exhibit 21: Global anti-inflammatory therapeutics market segmentation based on drug class 2016 (%)
Exhibit 22: Marketed anti-inflammatory biologicals
Exhibit 23: Global anti-inflammatory biologicals therapeutics market 2016-2021 ($ millions)
Exhibit 24: NSAIDs used for the treatment of autoimmune diseases
Exhibit 25: Global anti-inflammatory NSAIDs therapeutics market 2016-2021 ($ millions)
Exhibit 26: Global anti-inflammatory corticosteroid therapeutics market 2016-2021 ($ millions)
Exhibit 27: Global anti-inflammatory therapeutics market based on geography 2016 and 2021 (%)
Exhibit 28: Global anti-inflammatory therapeutics market based on geography 2016-2021 ($ millions)
Exhibit 29: Global anti-inflammatory therapeutics market based on geography 2016-2021 (%)
Exhibit 30: Market scenario in Americas
Exhibit 31: Anti-inflammatory therapeutics market in Americas 2016-2021 ($ millions)
Exhibit 32: Market scenario in EMEA
Exhibit 33: Anti-inflammatory therapeutics market in EMEA 2016-2021 ($ millions)
Exhibit 34: Market scenario in APAC
Exhibit 35: Anti-inflammatory therapeutics market in APAC 2016-2021 ($ millions)
Exhibit 36: Prevalence rate of types of IBD in the US 2015
Exhibit 37: Incidence rate of types of IBD in the US 2015
Exhibit 38: Biologics approvals by the US FDA to treat autoimmune diseases
Exhibit 39: Commonly used off-label anti-inflammatory therapeutics
Exhibit 40: Ongoing clinical trials with JAK inhibitors
Exhibit 41: Competitive structure analysis of global anti-inflammatory therapeutics market 2016
Exhibit 42: Competitive landscape snapshot
Exhibit 43: AbbVie: Key highlights
Exhibit 44: AbbVie: Strength assessment
Exhibit 45: AbbVie: Strategy assessment
Exhibit 46: AbbVie: Opportunity assessment
Exhibit 47: Amgen: Key highlights
Exhibit 48: Amgen: Strength assessment
Exhibit 49: Amgen: Strategy assessment
Exhibit 50: Amgen: Opportunity assessment
Exhibit 51: Johnson & Johnson: Key highlights
Exhibit 52: Johnson & Johnson: Strength assessment
Exhibit 53: Johnson & Johnson: Strategy assessment
Exhibit 54: Johnson & Johnson: Opportunity assessment
Exhibit 55: Pfizer: Key highlights
Exhibit 56: Pfizer: Strength assessment
Exhibit 57: Pfizer: Strategy assessment
Exhibit 58: Pfizer: Opportunity assessment

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *